Potential new therapeutics for Waldenstrom's macroglobulinemia

This publication has 21 references indexed in Scilit:

• Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
  Blood, 2002
• Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
  British Journal of Cancer, 2002
• Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity
  The Journal of Immunology, 2002
• Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
  Leukemia, 2001
• Mixed lineage kinase-dependent JNK activation is governed by interactions of scaffold protein JIP with MAPK module components
  The EMBO Journal, 2001
• Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
  Blood, 2001
• Type 4 Cyclic Adenosine Monophosphate Phosphodiesterase as a Therapeutic Target in Chronic Lymphocytic Leukemia
  Blood, 1998
• Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset
  The Journal of Experimental Medicine, 1998
• Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain.
  Genes & Development, 1993
• Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.
  The Journal of Experimental Medicine, 1993